

# *Development of Medication Measures for CKD & ESRD*

Christie R . Cahee, Pharm. D ., RPh  
Division of Acute and Chronic Disease Management  
Quality Measurement & Health Assessment Group  
Office of Clinical Standards & Quality, CMS



# Development of Medication Measures for CKD & ESRD

## MMA:

- Offers a new prescription drug benefit to eligible Medicare beneficiaries.
- Gave QIOs authority to provide quality improvement assistance pertaining to prescription drug therapy to Medicare Advantage plans under Part C and to prescription drug sponsors offering prescription drug plans under Part D.
- Mandated the distribution of comparative information to part D eligible individuals regarding the quality and performance of each PDP and MA-PD.

# Development of Medication Measures for CKD & ESRD

## Contract Award

- BearingPoint, Health Services Research & Management Group

# Development of Medication Measures for CKD & ESRD

- Development of medication measures that can be used for quality improvement and intervention and patient safety specific to the CKD and ESRD patient population based on Part D claims data and other available data sources.
- To identify and develop a set of measures that can be used by QIOs and ESRD Networks to establish a baseline for medication use in CKD and ESRD patients, and
- Identify drug-related issues specific to the CKD and ESRD patient populations.

# Development of Medication Measures for CKD & ESRD

## IOM Domains

- Safe
- Effective
- Patient-Centered
- Timely
- Efficient
- Equitable

# Development of Medication Measures for CKD & ESRD

## Medication Measure Categories

- Prescribing
  - Drug-drug interaction
  - Use of avoidable drugs in the CKD and/or ESRD populations
  - Generic prescribing and utilization ratios
  - Use of selected Medications within certain therapeutic categories

# Development of Medication Measures for CKD & ESRD

## Medication Measure Categories

- Disease-specific therapy
  - Drug-disease interactions
  - Therapeutic duplication
  - Therapeutic monitoring associate with specific drug utilization

# Development of Medication Measures for CKD & ESRD

## Medication Measure Categories

- Appropriateness of Therapy Measures- appropriate prescribing and drug regimen for specified disease states.

# Development of Medication Measures for CKD & ESRD

## Technical Expert Panel

- 15-non-government employed individuals & 3 government employed individuals with expertise in
  - Content
  - Methods
  - Claims data and
  - Quality improvement

# Development of Medication Measures for CKD & ESRD

## Current Status

- Preliminary list of proposed candidate measures
- 1<sup>st</sup> Technical Expert Panel (TEP) Meeting
  - January 26-27<sup>th</sup>, Baltimore
  - TEP summary report
  - Revision of proposed list of candidate measures

# Development of Medication Measures for CKD & ESRD

## Next Steps

- Medication Measures Input Document
- Stakeholder Comment Period
- 2<sup>nd</sup> Technical Expert Panel Meeting
- Stakeholders Meeting
- Development of technical specifications and formative testing of measures



# Development of Medication Measures for CKD & ESRD

---

**Christie R. Cahee**

**[Christie.cahee@cms.hhs.gov](mailto:Christie.cahee@cms.hhs.gov)**

**410-786-6614**

# Development of Medication Measures for CKD & ESRD

---

## Questions & Answers